Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon

Aurobino receives FDA nod for generic hypertension drug

Aurobindo Pharma has received approval from the FDA for Fosinopril Sodium and hydrochlorothiazide (HCT) tablets, a generic equivalent of Bristol-Myers Squibb's ACE inhibitor Monopril HCT.

FDA greenlights prasugrel, after one-year delay

The FDA this afternoon approved Daiichi Sankyo and Eli Lilly's Effient (prasugrel) tablets for the reduction of thrombotic cardiovascular events, including stent thrombosis, in patients with acute coronary syndromes who are managed with PCI.

AHA launches first iPhone app: First aid & CPR

Emergency information is just one touch away with the American Heart Association's new Pocket First Aid & CPR application for the Apple iPhone, released July 9.

Report: U.S. pays 40% more for top selling drugs, compared to EU

European prices of 170 best selling drugs averaged 40 percent less than U.S. prices in 2008, according to new research from healthcare market research firm Decision Resources.

Automated CPR Improves Survival—before and during PCI

Its increasingly clear that improved outcomes after an out-of-hospital cardiac arrest depend on having a host of protocols in place, rather than relying on one therapy or benchmark. Heres a look at automated CPR devices in the treatment of sudden cardiac arrest.

FDA rejects Takeda's diabetes drug, requesting more CV safety analysis

Takeda Global Research & Development Center, a wholly owned U.S. subsidiary of Takeda Pharmaceutical Company Limited, received on June 26 a complete response letter from the FDA, rejecting its new drug application for alogliptin, a selective dipeptidyl peptidase IV inhibitor, under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.

Bill Funds AEDs; Confusion about CPR

Sudden cardiac arrest (SCA) is the leading cause of death in the U.S., accounting for nearly 300,000 deaths every year more than lung cancer, breast cancer and HIV/AIDS combined.The chance of survival decreases by about 10 percent for every minute that a defibrillation shock from an AED is not received, however, AEDs are still not widely available and their use is often unknown.

Automated CPR and impedance threshold device work in concert

Its increasingly clear that improved outcomes after an out-of-hospital cardiac arrest depend on having a host of protocols in place, rather than relying on one therapy or benchmark. The combined use of an automated CPR device and an impedance threshold device is proving to be beneficial in this patient population.

Displaying 2209 - 2216 of 2325

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Design by Adaptive Theme
Trimed Popup
Trimed Popup